Astrocytoma/glioblastoma is the most common malignant form of brain cancer and is often unresponsive to current pharmacological therapies and surgical interventions. Despite several potential therapeutic agents against astrocytoma and glioblastoma, there are currently no effective therapies for astrocytoma, creating a great need for the identification of effective antitumor agents. The authors have developed a novel dual-reporter system in Trp53/Nf1-null astrocytoma cells to simultaneously and rapidly assay cell viability and cell cycle progression as evidenced by activity of the human E2F1 promoter in vitro. The dual-reporter high-throughput assay was used to screen experimental therapeutics for activity in Trp53/Nf1-null astrocytoma. Several compounds were identified demonstrating selectivity for astrocytoma over primary astrocytes. The dual-reporter system described here may be a valuable tool for identifying potential antitumor treatments that specifically target astrocytoma. (Journal of Biomolecular Screening 2008:795-803)
Central Brain Tumor Registry of the United States: Primary Brain Tumors in the United States-Statistical Report. Chicago: Central Brain Tumor Registry of the United States, 2002 .
2.
Ohgaki H.: Genetic pathways to glioblastomas. Neuropathology2005; 25:1-7.
3.
McLendon RE, Halperin EC: Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer2003;98:1745-1748.
4.
Gilbert MR, Loghin M.: The treatment of malignant gliomas. Curr Treat Options Neurol2005;7:293-303.
5.
Ichimura K., Bolin MB, Goike HM, Schmidt EE, Moshref A., Collins VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res2000;60:417-424.
6.
Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, et al: Alterations of the TP53 gene in human gliomas. Cancer Res1994;54:1324-1330.
7.
Watanabe K., Sato K., Biernat W., Tachibana O., von Ammon K., Ogata N., et al: Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res1997;3:523-530.
8.
von Deimling A., Eibl RH, Ohgaki H., Louis DN, von Ammon K., Petersen I., et al: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma . Cancer Res1992;52:2987-2990.
9.
Harris CC: p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis1996;17: 1187-1198.
10.
Weinstein JN , Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, et al: An information-intensive approach to the molecular pharmacology of cancer. Science1997;275:343-349.
11.
Huson S., Hughes R.: The Neurofibromatoses: A Pathogenetic and Clinical Overview. London: Chapman & Hall Medical, 1994.
12.
Martin GA, Viskochil D., Bollag G., McCabe PC, Crosier WJ, Haubruck H., et al: The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell1990;63:843-849.
13.
Cichowski K. , Shih TS, Schmitt E., Santiago S., Reilly K., McLaughlin ME, et al: Mouse models of tumor development in neurofibromatosis type 1. Science1999;286:2172-2176.
14.
Vogel KS, Klesse LJ, Velasco-Miguel S., Meyers K., Rushing EJ, Parada LF: Mouse tumor model for neurofibromatosis type 1. Science1999;286: 2176-2179.
15.
Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T.Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet2000;26:109-113.
16.
Uhrbom L., Nerio E., Holland EC: Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med2004;10:1257-1260.
Almond B., Hawkins E., Stecha P., Garvin D., Paguio A., Butler B., et al: A New Luminescence: Not Your Average Click Beetle. 2003. Retrieved from www.promega.com
Uht RM, Amos S., Martin PM, Riggan AE, Hussaini IM: The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. Oncogene2007;26:2885-2893.
21.
Ahn N., Tolwinski NS, Hsiao K., Goueli SA: U0126: An Inhibitor of MKK/ERK Signal Transduction in Mammalian Cells . Madison, WI: Promega Corporation , 1999.
22.
Barnouin K. , Dubuisson ML, Child ES, Fernandez de Mattos S., Glassford J., Medema RH, et al: H202 induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21Cip1 expression. J Biol Chem2002;277:13761-13770.
23.
Yamada HY, Gorbsky GJ: Cell-based expression cloning for identification of polypeptides that hypersensitize mammalian cells to mitotic arrest. Biol Proced Online2006;8:36-43.
24.
Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen1999;4:67-73.
25.
Assay Guidance Manual Version 4.1. 2005. Retrieved from http://www.ncgc.nih.gov/guidance/manual_toc.html
26.
Klautke G., Schutze M., Bombor I., Benecke R., Piek J., Fietkau R.: Concurrent chemoradiotherapy and adjuvant chemotherapy with topotecan for patients with glioblastoma multiforme. J Neurooncol2006;77:199-205.
27.
Adwankar MK , Khandalekar DD, Chitnis MP: Combination chemotherapy of early and advanced murine P388 leukaemia with bouvardin, cisdiamminedichloroplatinum and vincristine . Oncology1984;41:370-373.
28.
Jolad SD, Hoffmann JJ, Torrance SJ, Wiedhopf RM, Cole JR, Arora SK, et al: Bouvardin and deoxybouvardin, antitumor cyclic hexapeptides from Bouvardia ternifolia (Rubiaceae). J Am Chem Soc1977;99:8040-8044.
